Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK of Repeated SC Ronapreve in Healthy Adults
NCT04519437Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jul 2020
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Ronapreve with Placebo (2 arms). Primary endpoints: Incidence of adverse event of special interests (AESIs) that occur within 4 days of study drug administration, Concentrations of REGN10933 in serum over time up to 52 weeks and 1 more. Started Jul 2020; status: completed.
02
Drugs
casirivimab + imdevimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04519437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04519437.